Analyst Price Target is $122.70
▲ +98.87% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for TransMedics Group in the last 3 months. The average price target is $122.70, with a high forecast of $178.00 and a low forecast of $75.00. The average price target represents a 98.87% upside from the last price of $61.70.
Current Consensus is
Moderate Buy
The current consensus among 11 investment analysts is to moderate buy stock in TransMedics Group. This rating changed within the last month from a Buy consensus rating.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More
